LYB
43
2
MSFT
55
-2
CTSH
57
-3
SCHW
67
2
KMB
42
-2
WY
64
4
EQT
50
-4
FOX
50
2
MU
34
-2
GD
44
2
IR
65
-3
GOOGL
50
2
L
68
3
O
28
4
CVS
57
5
GWW
72
-4
MRK
40
5
SO
64
2
AA
56
-7
PSX
47
-3
LYB
43
2
MSFT
55
-2
CTSH
57
-3
SCHW
67
2
KMB
42
-2
WY
64
4
EQT
50
-4
FOX
50
2
MU
34
-2
GD
44
2
IR
65
-3
GOOGL
50
2
L
68
3
O
28
4
CVS
57
5
GWW
72
-4
MRK
40
5
SO
64
2
AA
56
-7
PSX
47
-3
Financhill
Back

Protagonist Therapeutics Quote, Financials, Valuation and Earnings

Invest. Do Good. Get Rewarded. Just $0.26/Share!

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
41

PTGX
Protagonist Therapeutics

Last Price:
44.91
Seasonality Move:
11.46%

7 Day Trial

ALL ACCESS PASS

$ 7

Say this - unlock as much as $1,250 every Friday

Click here for full details.

Protagonist Therapeutics Price Quote

$44.91
-0.04 (0.18%)
(Updated: November 28, 2024 at 5:43 AM ET)

Protagonist Therapeutics Key Stats

Sell
41
Protagonist Therapeutics (PTGX) is a Sell
Day range:
$43.80 - $45.60
52-week range:
$17.13 - $48.89
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
8.55
P/B ratio:
5.02%
Volume:
569.5K
Avg. volume:
705.4K
1-year change:
158.04%
Market cap:
$2.7B
Revenue:
$60M
EPS:
$2.66

How Much Does Protagonist Therapeutics Make?

Is Protagonist Therapeutics Growing As A Company?

Data Unavailable

Protagonist Therapeutics Stock Price Performance

What Is Protagonist Therapeutics 52-Week High & Low?

Protagonist Therapeutics Price To Free Cash Flow

Is It Risky To Buy Protagonist Therapeutics?

Is Protagonist Therapeutics Cash Flow Positive?

  • What Is PTGX Cash Flow From Operations?
    Cash flow from operations (TTM) is $230.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $22.3M
  • What Is Protagonist Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$352M

Protagonist Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    PTGX return on invested capital is 37.59%
  • What Is Protagonist Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is 33.69%
  • What Is PTGX Return On Equity?
    ROE is a measure of profitability and is 37.59%

Protagonist Therapeutics Earnings Date & Stock Price

Protagonist Therapeutics Competitors

Protagonist Therapeutics Dividend Yield

Protagonist Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% -1.89%
Revenue: 0% 157.93%

Analyst Recommendations

Buy Recommendations: 5
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 56.38
Upside from Last Price: 25.42%

Major Shareholders

  • How many PTGX shares are owned by institutional investors?
    107.8M PTGX shares are owned by institutional investors
  • How many PTGX shares are owned by insiders?
    1.1M PTGX shares are owned by insiders